(Q83145997)
English
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
scientific article published on 27 December 2011
Statements
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer (English)
Ignace Vergote
Jan Lubinski
Ursula Matulonis
Stan B Kaye
Joo Ern Ang
Charlie Gourley
Beth Y Karlan
Amit Amnon
Katherine M Bell-McGuinn
Lee-May Chen
Michael Friedlander
Tamar Safra
Mark Wickens
Elizabeth S Lowe
James Carmichael
27 December 2011